Abstract
There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Current Pharmaceutical Design
Title: Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Volume: 17 Issue: 24
Author(s): David Cassiman
Affiliation:
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Abstract: There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Export Options
About this article
Cite this article as:
Cassiman David, Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247596
DOI https://dx.doi.org/10.2174/138161211797247596 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science MicroRNAs in Atrial Fibrillation
Current Medicinal Chemistry Statins and Oxidative Stress in the Cardiovascular System
Current Pharmaceutical Design Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Therapy Against Ischemic Injury
Current Pharmaceutical Design Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases
Cardiovascular & Hematological Disorders-Drug Targets Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design